Drug Profile
Seviprotimut L - Polynoma
Alternative Names: Melanoma vaccine - Polynoma; POL-103A; Polyvalent, shed-antigen melanoma vaccine; Seviprotimut-L - Polynoma; Seviprotimut-L polyvalent melanoma vaccineLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator Polynoma
- Developer New York University School of Medicine; Polynoma
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Malignant melanoma
Most Recent Events
- 11 Jan 2022 Polynoma reaches an agreement with the US FDA under a Special Protocol Assessment (SPA) on a pivotal phase III study in Malignant melanoma (Adjuvant therapy)
- 11 Jan 2022 Efficacy and safety data from the phase III MAVIS trial in Malignant melanoma released by Polynoma
- 11 Jan 2022 Polynoma plans a pivotal phase III trial for Malignant melanoma (Adjuvant therapy)